

LETTER TO THE EDITOR

Open Access

A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD

Renate K Hukema^{1,7*†}, Frédérique W Riemsdijk^{1,2†}, Shamiram Melhem², Herma C van der Linde¹, Lies-Anne WFM Severijnen¹, Dieter Edbauer³, Alex Maas⁴, Nicolas Charlet-Berguerand⁵, Rob Willemsen^{1†} and John C van Swieten^{2,6†}

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two neurodegenerative disorders that share clinical, genetic and pathological overlap. In 2011, a hexanucleotide repeat (GGGGCC) expansion in the 'chromosome 9 open reading frame 72' (C9orf72) gene was identified as a cause of FTD and ALS [1,2]. This mutation has proven to be the most common genetic defect in the neurodegenerative field, especially in FTD and ALS [3]. Patients harboring the C9orf72 repeat expansion can develop FTD, ALS or both and are therefore associated with wide clinical diversity [4]. There have been multiple hypotheses about the underlying mechanisms by which the repeat expansion leads to neuropathology, including loss-of-function caused by haploinsufficiency of the endogenous C9orf72 protein product or gain-of-function induced by either RNA or protein toxicity. Either free RNA molecules containing the repeat expansion or RNA foci that sequester proteins could be toxic for cells. Alternatively, a pathogenic mechanism has been proposed for the production of toxic dipeptide repeat proteins (DPR) by repeat-associated non-AUG translation (RAN) of the repeat [5,6]. Interestingly, to differentiate between repeat "RNA-only" and DPR protein toxicity fruit fly models carrying a range of pure and RNA-only repeats have been generated. These studies demonstrated that the major toxic species were the DPR proteins [7].

Here we report on an "RNA-only" gain-of-function mouse model. To study the intrinsic effect of the repeat without assessing its effect on the C9orf72 gene, we created a spatially and temporally inducible transgenic mouse model. This mouse model has a repeat size of 80 GGGGCC-repeats, without human flanking regions, which may affect repeat translation. This repeat was cloned in the 5' UTR of a GFP reporter gene and controlled by a tetracycline responsive element (TRE) promoter (Figure 1A). To enable expression of the TRE-construct we created bigenic mice that possess both the TRE-construct and the tetracycline-responsive transcriptional activator (rtTA) under a general heterogeneous nuclear ribonucleoprotein (hnRNP) promoter [8]. Expression of the repeat was turned on after weaning by adding doxycycline (dox) to the drinking water. Expression of the repeat construct can be stopped at any time by withdrawal of dox, allowing for reversibility studies (Figure 1A; more information about the creation of the model can be found in Additional file 1). After generation of transgenic mice, the repeat size remained stable for multiple generations (data not shown). GFP expression was seen in bigenic mice as soon as 4 days after dox treatment started and remained stable over time (assessed by western blot of liver homogenates, data not shown). Next to liver, multiple other tissues showed GFP expression including lung, kidney and brain; with most prominent expression in the striatum (Figure 1B) and the cuneate nucleus in the brainstem.

Both ubiquitin-positive, TDP-43-positive and TDP-43 negative neuronal and cytoplasmic inclusions are pathological hallmarks in post mortem brain tissue from

* Correspondence: r.hukema@erasmusmc.nl

†Equal contributors

¹Department of Clinical Genetics, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands

⁷PO Box 2040, 3000 CA Rotterdam, The Netherlands

Full list of author information is available at the end of the article




Figure 1 Expression of 80GGGGCC-repeats leads to the formation of ubiquitin-positive inclusions in mouse brain. **A)** Schematic of the model used to create the inducible mice. Simultaneous expression of rtTA and doxycycline treatment are needed to drive expression of the TRE-80GGGGCC-eGFP construct. PCR for determining repeat size in three transgenic mice containing the repeat construct. **B)** GFP expression in the striatum of bigenic mice after 12 weeks dox treatment. **C)** Intranuclear (arrows) and neuropil (arrowheads) ubiquitin-positive inclusions in the striatum of bigenic mice after 12 weeks dox treatment.

C9orf72 FTD and ALS patients. We used the presence of inclusions as a readout for the effect of expression of the repeat in our “RNA-only” gain-of-function ALS/FTD model [9,10]. We found ubiquitin-positive inclusions in those brain regions that express high levels of GFP, including the striatum (Figure 1C) and the cuneate nucleus of bigenic mice after twelve weeks of dox treatment ($n = 7$ mice per group). Inclusions were found in the nuclei and the neuropil in striatum and mainly in the nuclei in the cuneate nucleus. The presence of ubiquitin-positive inclusions in our mouse model is a shared phenomenon with non-C9orf72 mouse models of ALS and FTD [11,12]. We did not observe any TDP-43 positive nor p409/410 TDP-43 positive inclusions in our mouse model after twelve weeks of dox treatment, despite the positive staining in a C9orf72 patient hippocampus control (data not shown). TDP-43 inclusions might only appear after prolonged expression of the repeat or additional genetic or environmental factors might be needed to drive TDP-43 dysfunction. Importantly, TDP-43 function could also be affected without the presence of TDP-43 positive aggregates [13]. The absence of DPR pathology was assessed with a poly-GA antibody [6]. We could not detect poly-GA aggregation in brain tissue from bigenic mice, but only revealed GA-positive inclusions in C9orf72 patient hippocampus control

material illustrating lack of DPR pathology in this mouse model (Figure 2). The mice did not develop any obvious behavioral phenotype and showed no cell loss. The neurotoxic effect of the C9orf72 hexarepeat expansion has been suggested by both RNA- and protein-mediated pathology [7]. Due to lack of DPR pathology, this mouse is a good model to investigate whether toxicity can be driven by the repeat RNA only. Future studies focusing on molecular changes and behavior deficits in our mouse model can provide additional insight in disease progression, reversibility and create options for therapeutic intervention. In conclusion, we demonstrate that solely expression of the GGGGCC repeat outside the C9orf72 context results in ubiquitin-positive inclusions, which is a pathological hallmark in postmortem brain from ALS and FTD patients. Our data on this first C9orf72 mouse model argues in favor for a gain-of-function pathological mechanism in C9orf72 associated ALS and FTD.

All animal experiments were conducted with the permission of the local animal welfare committee (DEC). Experiments on human brain material were done under informed consent and approved by the Medical Ethical Test Committee (METC). Human paraffin embedded brain material was provided by the Dutch brain bank (Nederlandse Hersenbank NHB).




Figure 2 Absence of DPR pathology in brain of 80GGGGCC RNA expressing mouse. A) GA positive inclusions in the hippocampus of C9orf72FTD patient. **B)** the striatum of bigenic mice treated with dox for 12 weeks shows no GA positive inclusions.

Additional file

Additional file 1: Supplementary material and methods.

Abbreviations

ALS: Amyotrophic lateral sclerosis; FTD: Frontotemporal dementia; C9orf72: Chromosome 9 open reading frame 72; DPR: Dipeptide repeat proteins; RAN: Repeat-associated non-AUG; TRE: Tetracycline responsive element; rtTA: Tetracycline-responsive transcriptional activator; hnRNP: Heterogeneous nuclear ribonucleoprotein; dox: Doxycycline.

Competing interests

All authors met the ICMJE requirements for authorship, have seen and agree with the contents of the manuscript and confirm that the manuscript

represents integer work. We certify that the submission is not under review at any other publisher. There are no previous reports that might be regarded as redundant publication. We declare no financial or other relationships that might lead to a perceived conflict of interest.

Authors' contributions

RKH created the mouse model, supervised the experiments, and drafted the manuscript. FWR performed experiments, interpreted results, and drafted the manuscript. SM performed experiments and interpreted results. HCvdL: performed experiments and interpreted results. LAWfMS performed experiments and interpreted results. DE supplied antibodies. AM generated transgenic mice. NCB cloned the repeat. RW interpreted results, supervised experiments and drafted the manuscript. JCVS interpreted results, supervised experiments and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors wish to acknowledge the contribution of Tom de Vries Lentsch, Ruud Koppenol, and Alan Mrcic. This work was supported by Stichting Alzheimer Nederland grant number WE03.2012-XX [to JCVs and RW], JPND grant RimoD [to JCVs], by E-Rare project number 40-42900-98-1001/113301201 from ZonMW [to RKH], and the European Community's Health Seventh Framework Programme FP7/2013-2018 under grant agreement n° 617198 [to DE].

Author details

¹Department of Clinical Genetics, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands. ²Department of Neurology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands. ³German Center for Neurodegenerative Diseases, 81337 Munich, Germany. ⁴Department of Cell Biology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands. ⁵Department of Neurobiology and Genetics, IGBMC, INSERM U964, CNRS UMR7104, University of Strasbourg, Illkirch, France. ⁶Department of Neurology, Neuroscience Campus Amsterdam, 1007 MB Amsterdam, The Netherlands. ⁷PO Box 2040, 3000 CA Rotterdam, The Netherlands.

Received: 20 November 2014 Accepted: 25 November 2014
Published online: 13 December 2014

References

1. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72(2):257–268, doi:10.1016/j.neuron.2011.09.010
2. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seelley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72(2):245–256, doi:10.1016/j.neuron.2011.09.011
3. Cruts M, Gijssels I, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013) Current insights into the C9orf72 repeat expansion diseases of the FTD/ALS spectrum. *Trends Neurosci* 36(8):450–459, doi:10.1016/j.tins.2013.04.010
4. Yokoyama JS, Miller BL (2014) C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. *Am J Neurodegener Dis* 3(1):1–18
5. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, DeJesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, Boylan KB, Dickson DW, Petrucelli L (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. *Neuron*. doi: 10.1016/j.neuron.2013.02.004
6. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTD/ALS. *Science*. doi: 10.1126/science.1232927
7. Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woolfaccott IO, Pietrzyk J, Cleverley K, Nicoll AJ, Pickering-Brown S, Dols J, Cabecinha M, Hendrich O, Fratta P, Fisher EM, Partridge L, Isaacs AM (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. *Science* 345(6201):1192–1194, doi:10.1126/science.1256800
8. Hukema RK, Buijsen RA, Raske C, Severijnen LA, Nieuwenhuizen-Bakker I, Minneboo M, Maas A, de Crom R, Kros JM, Hagerman PJ, Berman RF, Willemsen R (2014) Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo. *Cell Cycle* 13(16):2600–2608, doi:10.4161/15384101.2014.943112
9. Mackenzie IR, Frick P, Neumann M (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. *Acta Neuropathol* 127(3):347–357, doi:10.1007/s00401-013-1232-4
10. Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobagyi T, Shaw CE (2011) p62 positive, TDP-43 negative,

- neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTD and MND/ALS. *Acta Neuropathol* 122(6):691–702, doi:10.1007/s00401-011-0911-2
11. Roberson ED (2012) Mouse models of frontotemporal dementia. *Ann Neurol* 72(6):837–849, doi:10.1002/ana.23722
 12. Waite AJ, Baumer D, East S, Neal J, Morris HR, Ansgore O, Blake DJ (2014) Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. *Neurobiol Aging* 35(7):1779 e1775–1779 e1713, doi:10.1016/j.neurobiolaging.2014.01.016
 13. Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM, Wong PC (2012) Rodent models of TDP-43: recent advances. *Brain Res* 1462:26–39, doi:10.1016/j.brainres.2012.04.031

doi:10.1186/s40478-014-0166-y

Cite this article as: Hukema et al.: A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD. *Acta Neuropathologica Communications* 2014 **2**:166.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

